Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunoprecise Antibodies Ltd (IPA)

Immunoprecise Antibodies Ltd (IPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,126
  • Shares Outstanding, K 28,832
  • Annual Sales, $ 18,160 K
  • Annual Income, $ -20,130 K
  • EBIT $ -9 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.13
  • Price/Sales 0.65
  • Price/Cash Flow N/A
  • Price/Book 0.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.78
  • Most Recent Earnings $-0.11 on 09/16/24
  • Next Earnings Date 12/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 471.87% ( -1.71%)
  • Historical Volatility 106.20%
  • IV Percentile 88%
  • IV Rank 43.47%
  • IV High 1,002.30% on 01/10/24
  • IV Low 64.04% on 02/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 74
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 478
  • Open Int (30-Day) 605

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3354 +4.32%
on 11/21/24
0.6950 -49.65%
on 10/25/24
-0.1853 (-34.62%)
since 10/21/24
3-Month
0.3354 +4.32%
on 11/21/24
0.9200 -61.97%
on 08/22/24
-0.5400 (-60.68%)
since 08/21/24
52-Week
0.3354 +4.32%
on 11/21/24
2.6000 -86.54%
on 02/06/24
-0.9401 (-72.88%)
since 11/21/23

Most Recent Stories

More News
Light Week for Macroeconomic Figures in U.S.

Monday U.S. Economic Lookahead Consumer Credit (May) Featured Earnings Greenbrier ...

GBX : 65.75 (+2.19%)
IPA : 0.3322 (-13.92%)
AMX : 15.17 (+1.27%)
HELE : 69.01 (+3.31%)
SGH : 20.85 (+0.43%)
WDFC : 280.60 (+1.08%)
PSMT : 88.07 (+0.42%)
AZZ : 92.87 (+5.94%)
PEP : 159.76 (+0.64%)
PRGS : 69.32 (+3.29%)
CTAS : 221.10 (+1.07%)
JPM : 244.76 (+1.65%)
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced a research collaboration...

IPA : 0.3322 (-13.92%)
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), the parent company of BioKey and affiliate of BioStrand, announced today that the EPO has issued a “Decision...

IPA : 0.3322 (-13.92%)
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, is pleased to announce that its wholly...

IPA : 0.3322 (-13.92%)
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal...

IPA : 0.3322 (-13.92%)
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that Talem Therapeutics...

IPA : 0.3322 (-13.92%)
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss...

IPA : 0.3322 (-13.92%)
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for second quarter fiscal...

IPA : 0.3322 (-13.92%)
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that its subsidiary, BioStrand BV, has completed...

IPA : 0.3322 (-13.92%)
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss...

IPA : 0.3322 (-13.92%)

Business Summary

ImmunoPrecise Antibodies Ltd. is a technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. ImmunoPrecise Antibodies Ltd. is based in VICTORIA.

See More

Key Turning Points

3rd Resistance Point 0.4491
2nd Resistance Point 0.4286
1st Resistance Point 0.4072
Last Price 0.3322
1st Support Level 0.3653
2nd Support Level 0.3448
3rd Support Level 0.3234

See More

52-Week High 2.6000
Fibonacci 61.8% 1.7349
Fibonacci 50% 1.4677
Fibonacci 38.2% 1.2005
Last Price 0.3322
52-Week Low 0.3354

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar